Sleep disorders in primary antiphospholipid syndrome

The objective of this study was to evaluate the sleep quality, the presence of sleep disorders in patients with primary antiphospholipid syndrome (pAPS), and their possible clinical and laboratory associations. This was a cross-sectional study of 40 consecutive pAPS patients and 211 healthy age- and sex-matched controls. Demographic and clinical data, drug use, and antiphospholipid antibodies were evaluated. Sleep was evaluated using the Pittsburgh Sleep Quality Index (PSQI). pAPS patients had significantly worse sleep quality than healthy controls. Analyzing the individual components, pAPS had worse scores in five of seven components: sleep duration (p=0.002), habitual sleep efficiency (p=0.003), sleep disturbance (p<0.001), use of sleep medication (p<0.001), and daytime somnolence (p=0.03). No association of sleep disturbance and demographic, clinical, and laboratory features of the disease was observed. This is the first study to analyze sleep quality in pAPS. We observed that pAPS had significant worse sleep quality; however, no demographic, clinical, or laboratory feature was associated with sleep disturbance.